Flora Growth (FLGC) Q3 2024 earnings summary

Executive summary

• Q3 2024 revenue was $12.5M, down from $17.3M in Q3 2023, mainly due to lower sales at JustCBD and Vessel, and market headwinds in the U.S. and Australia.

• Net loss for Q3 2024 was $3.8M, reversing a net income of $1.1M in Q3 2023; nine-month net loss narrowed to $9.8M from $47.3M year-over-year.

• Operating expenses for Q3 rose to $6.5M from $5.5M; nine-month operating expenses dropped to $19.6M from $57.2M year-over-year.

• Expanded product lines, launched THC-infused beverages in the U.S., and entered the German parallel import business amid regulatory liberalization.

• Board and management changes included new leadership in Europe and appointments to the board.

Financial highlights

• Q3 2024 revenue: $12.5M (down 28% year-over-year); nine months: $46.2M (down 20%).

• Q3 2024 net loss: $3.8M (vs. $1.1M net income in Q3 2023); nine months: $9.8M net loss (vs. $47.3M net loss in 2023).

• Q3 2024 operating expenses: $6.5M (up from $5.5M); nine-month operating expenses: $19.6M (down from $57.2M).

• Cash used in operations for nine months: $3.7M (improved from $7.3M in 2023).

• Ended Q3 with $4.2M in cash and $21.3M in current assets, including $7.9M in saleable inventory.

Outlook and guidance

• U.S. beverage segment and German parallel import business expected to be primary growth drivers.

• Gross margin guidance targets low 30% to high 20% range as German business model shifts and parallel import revenues grow.

• Margin expansion expected as new initiatives in Germany mature over the next few quarters.

• Management highlights substantial doubt about ability to continue as a going concern without additional capital.

• Update on margin progress anticipated in Q1 2025 after new leadership team settles.